There are currently 89 active clinical trials seeking participants for Lymphoma research studies. The states with the highest number of trials for Lymphoma participants are Ohio, Illinois, California and New York.
Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors
NCT04169321
Recruiting
First in Human Safety of [68Ga]-NOTA-hGZP PET Imaging in subjects with cancer undergoing treatment with a checkpoint inhibitor either as a monotherapy of in combination I-O therapy
Gender:
All
Ages:
18 years and above
Trial Updated:
02/17/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +2 locations
Conditions: Solid Tumor, Unspecified, Adult, Lymphoma
Register for Updates
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT05366881
Recruiting
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mort... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
02/15/2024
Locations: City of Hope, Duarte, California +14 locations
Conditions: Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Stomach Cancer, Head and Neck Cancer, Hepatobiliary Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cancer, Sarcoma, Thyroid Cancer
Register for Updates
A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma
NCT04970992
Recruiting
The primary goal of this Phase 1 study is to characterize the safety and tolerability of DZ-002 and establish the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of DZ-002 administered on a weekly schedule in patients with solid tumors. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of DZ-002 will also be assessed.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/15/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Solid Tumor, Lymphoma
Register for Updates
Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma
NCT05464823
Recruiting
To learn more about the usefulness of molecular testing with the Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
NCT05346809
Recruiting
The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the immune system so that upon recovery from the transplant, the immune system can fight the cancer. This study will have two arms. On one arm (control arm), participants will receive standard transplant procedures and on the other arm (experimental arm), p... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Columbia University, New York, New York
Conditions: Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
Register for Updates
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
NCT05878691
Recruiting
This is first in human (FIH) study to a) evaluate the safety and tolerability profile of GRC54276, b) determine the maximum tolerated dose (MTD) and recommended Phase 2 doses (RP2D), and c) pharmacokinetic profile of GRC54276 alone and in combination with pembrolizumab or atezolizumab in participants with advanced solid tumors and lymphomas.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: Carolina BioOncology Institute, Huntersville, North Carolina +17 locations
Conditions: Advanced Solid Tumor, Lymphoma
Register for Updates
Collecting and Storing Tissue From Young Patients With Cancer
NCT00898755
Recruiting
This laboratory study is collecting and storing tissue, blood, and bone marrow samples from young patients with cancer. Collecting and storing samples of tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
Gender:
All
Ages:
21 years and below
Trial Updated:
01/29/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +68 locations
Conditions: Acute Lymphoblastic Leukemia, Rhabdomyosarcoma, Acute Myeloid Leukemia, Central Nervous System Neoplasm, Ewing Sarcoma, Germ Cell Tumor, Leukemia, Lymphoma, Malignant Neoplasm, Neuroblastoma, Osteosarcoma, Retinoblastoma, Rhabdoid Tumor, Soft Tissue Sarcoma
Register for Updates
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
NCT03995147
Recruiting
This study will research untreated non-germinal center diffuse large B cell lymphoma and what causes the disease and the way patients respond to pembrolizumab combined with R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/26/2024
Locations: The University of Chicago, Chicago, Illinois
Conditions: B Cell Lymphoma, Lymphoma, Lymphoma, B-Cell, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Register for Updates
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
NCT05019976
Recruiting
This study focuses on using shortened courses of radiation for participants with relapsed/refractory Hodgkin/Non-Hodgkin lymphoma. Treatment radiation over 5-6 weeks is often standard of care for many people with lymphoma, but doctors leading this study aim to find out if using radiation for a shorter period of time can be safe for treating lymphoma and if so, what is the safest shortened dose of radiation for participants.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/26/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Non-hodgkin Lymphoma, Hodgkin Lymphoma, Lymphoma
Register for Updates
A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
NCT04983810
Recruiting
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, PK, pharmacodynamics, PGx, and efficacy of fadraciclib administered orally BID. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma who have progressed despite having standard therapy or for which no standard therapy exists.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: City of Hope, Duarte, California +3 locations
Conditions: Solid Tumor, Adult, Lymphoma
Register for Updates
Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy
NCT05763563
Recruiting
The purpose of the study is to evaluate an exercise program for individuals preparing for Chimeric Antigen Receptor (CAR) T-cell immunotherapy for hematological malignancies.
Gender:
All
Ages:
65 years and above
Trial Updated:
01/24/2024
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Lymphoma, Leukemia, Myeloma
Register for Updates
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
NCT01788839
Recruiting
The purpose of this study is to see how cancer treatment affects sexual and reproductive function. The patient will also be asked to participate in blood draws to see if and how cancer treatment affects the ovaries and the ability to have children (fertility). These blood draws are optional and the patient can still participate in the questionnaire portion of the study even if they choose not to have their blood drawn.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/23/2024
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +6 locations
Conditions: Breast Cancer, Lymphoma, Hodgkin's Lymphoma
Register for Updates